Chardan Capital Markets downgraded Arbutus Biopharma (NASDAQ: ABUS) from Neutral to Sell with a price target of $2.75, saying competition ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE